Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company focused on the research and development of drug products that are delivered into and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced it will be meeting with several U.S. investment bankers, analysts and fund managers during J.P. Morgan's 29th annual Healthcare Conference held from January 10th to January 13th, 2011, in San Francisco, California.
In preparation for these meetings, Nuvo has updated its investor presentation which can be found on Nuvo's website at www.nuvoresearch.com.
The presentation includes updated Pennsaid prescription data that shows U.S. prescriptions for Pennsaid in the fourth quarter of 2010 are tracking approximately 20% higher than the third quarter of 2010. Final third quarter prescriptions were 26,600.